Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Sarepta Therapeutics Inc  surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc.

Sarepta surges after Pfizer gene therapy data raises safety concerns

Sarepta Therapeutics stock rocketed in high volume Friday after Pfizer said its gene therapy test is on pause following serious side effects in two boys with Duchenne muscular dystrophy.
The post Gene Therapy Battle: Pfizer's Test Results Sent This Biotech Stock Flying appeared first on Investor's Business Daily.

Gene Therapy Battle: Pfizer's Test Results Sent This Biotech Stock Flying

Investors need to pay close attention to Sarepta Therapeutics (SRPT) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock?

Sarepta Therapeutics was one of my best trades and biggest mistakes. Now, I want back SRPT despite paying double what I sold it for over a year ago.

Sarepta: When You Sell Too Early And Want Back In

Upcoming Pfizer data reveal will end the overhang on Sarepta's stock.

Sarepta Therapeutics: Judgement Day Cometh

Sarepta Therapeutics will face a "whale" of an overhang Friday when Dow Jones stock Pfizer unveils the results of its gene therapy in Duchenne muscular dystrophy, an analyst said Monday.

This Biotech Stock Is Facing A 'Whale' As Pfizer Unveils Gene Therapy Data

CRISPR Therapeutics

Vertex Pharmaceuticals

Vertex Pharmaceuticals recently doubled down on its gene editing collaboration with CRISPR Therapeutics, but it's miles behind an arguably simpler solution.

Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Sarepta Therapeutics (SRPT) Up 2.9% Since Last Earnings Report: Can It Continue?

ABIOMED

Aptiv Holdings Ltd

Grupo Aeroportuario del Sureste SAB de CV

Intuit

Zoetis

Chief investment officer and chief executive officer of Sands Capital Management, Frank Sands (Trades, Portfolio), bought shares of the following stocks in the fourth quarter of 2018 and first quarter of 2019.

7 Stocks Frank Sands Continues to Buy

Anthem

Alibaba

Microchip Technology

Tapestry

Valero Energy

World Wrestling Entertainment

If you’re looking for a quick portfolio boost, look no further. Here are 7 stocks to buy with tons of upside according to top analysts.

7 Stocks to Buy for Over 20% Upside Potential

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2019 Results - Earnings Call Transcript

Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand.

Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up

Pfizer's upcoming data reveal created a perfect sell the news event for Sarepta.

Sarepta: Buy The Pfizer Selloff

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

A. O. Smith

Dollar Tree

Want to invest like the great value investor? These stocks might appeal to you.

Three Stocks Warren Buffett Would Love

Sarepta Therapeutics Inc. has had a bearish month after a couple years of stellar price appreciation which could be a concern for investors wondering what's going on

What's Wrong With Sarepta Therapeutics?

Sarepta Therapeutics (SRPT) Down 17.7% Since Last Earnings Report: Can It Rebound?

Sarepta (SRPT) key pipeline candidate leads to statistically significant increase in dystrophin production in ESSENCE study NDA to be filed mid-2019.

Sarepta (SRPT) Reports Positive Interim Results for DMD Drug

Sarepta Therapeutics said Thursday it's planning to ask for Food and Drug Administration approval of another Duchenne muscular dystrophy treatment in mid-2019.

How This Biotech Stock Is Reinforcing Its Ironclad Hold On A Key Market

Shares of Sarepta Therapeutics rose 3.4% in premarket trade Thursday.

Sarepta Therapeutics stock up 3.4% after Phase 3 interim analysis shows positive results for DMD drug

Sarepta Therapeutics released positive results from its early-stage study using micro-dystrophin to treat patients with Duchenne muscular dystrophy.

Sarepta Looks To Remain The Leader In DMD Treatment With Latest Gene Therapy Data

It's hard not to get excited about this company's experimental gene therapy for Duchenne muscular dystrophy.

News for Sarepta Therapeutics Stock (SRPT)